Sharron Gargosky - Prima Biomed Chief Technical Officer
Executive
Dr. Sharron Gargosky is Chief Technical Officer of Prima Biomed Ltd. and was with Prima BioMed since August 2010. Dr. Gargosky has over 19 years experience in the biotechnology and pharmaceutical industries and has worked in senior positions in organizations that have successfully received FDA approval for orphan drugs. She is responsible for managing the clinical team working on the CVac immunotherapy cancer vaccine. Prior to joining Prima BioMed Dr. Gargosky was a member of ILMU consulting LLC where she provided project management and operational expertise on pharmaceutical drug and biologic development from early research to Phase IV Trials and the FDA approval process. Dr. Gargosky has also previously held the positions of Chief Scientific Officer at Pulse Health LLC in Portland in the USA and Chief Scientific Officer and Senior Vice President of Corporationrationrate Development at Hyperion Therapeutics Inc. in San Francisco. At Ucyclyd Pharma she managed the approval of orphan drug products and the development of the NCE and within Medics Pharmaceuticals the successful BLA submission and approval for Reloxin. As Vice President of Business Development for Diagnostic System Laboratories she was responsible for business expansion through evaluation and implementation of new growth opportunities and patent portfolio management since 2012.
Age | 50 |
Tenure | 12 years |
Professional Marks | Ph.D |
Phone | 61 2 8315 7003 |
Web | http://www.primabiomed.com.au |
Prima Biomed Management Efficiency
The company has return on total asset (ROA) of (15.25) % which means that it has lost $15.25 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (30.29) %, meaning that it created substantial loss on money invested by shareholders. Prima Biomed's management efficiency ratios could be used to measure how well Prima Biomed manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 4.6 M in liabilities with Debt to Equity (D/E) ratio of 21.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Prima Biomed has a current ratio of 5.93, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Prima Biomed until it has trouble settling it off, either with new capital or with free cash flow. So, Prima Biomed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Prima Biomed sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Prima to invest in growth at high rates of return. When we think about Prima Biomed's use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | EXECUTIVE Age | ||
Debra SPHR | Mustang Bio | N/A | |
Christopher Gulden | SL Green Realty | N/A | |
Steven Durels | SL Green Realty | 65 | |
Josephine Hellschlienger | Abcellera BiologicsInc | N/A | |
Kathleen BA | Abcellera BiologicsInc | N/A | |
Richard MD | Calliditas Therapeutics | 60 | |
David Ferraro | Calliditas Therapeutics | N/A | |
Richard MS | Mustang Bio | N/A | |
Robyn MA | Acumen Pharmaceuticals | N/A | |
CGA CPA | Abcellera BiologicsInc | N/A | |
Ping Rawson | Dyadic International | 43 | |
Esq JD | Abcellera BiologicsInc | 54 | |
Richard Currenti | SL Green Realty | N/A | |
Maggie Hui | SL Green Realty | 60 | |
Neil MBA | Abcellera BiologicsInc | 54 | |
JD Esq | Acumen Pharmaceuticals | 53 | |
Doug BA | Dyadic International | N/A | |
Bruce MD | Mustang Bio | N/A | |
Teona Johnson | Calliditas Therapeutics | N/A | |
Murray McCutcheon | Abcellera BiologicsInc | N/A | |
Peter Carney | Mustang Bio | 37 |
Management Performance
Return On Equity | -30.29 | |||
Return On Asset | -15.25 |
Prima Biomed Leadership Team
Elected by the shareholders, the Prima Biomed's board of directors comprises two types of representatives: Prima Biomed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Prima. The board's role is to monitor Prima Biomed's management team and ensure that shareholders' interests are well served. Prima Biomed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Prima Biomed's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pete Meyers, Non-Executive Director | ||
Russell Howard, Non-Executive Director | ||
Larisa Chisholm, Director of Industry Liaison and Devel. and Director of Intellectual Property | ||
Tom Bloomfield, Joint Company Secretary | ||
YueLing Wong, Non-Executive Deputy Chairman of the Board | ||
Frederic Triebel, Chief Scientific Officer & Chief Medical Officer | ||
Deanne Miller, General Counsel, Company Secretary | ||
Sharron Gargosky, Chief Technical Officer | ||
Grant Chamberlain, Non-Executive Director | ||
Lucy Turnbull, Non-Executive Chairman of the Board | ||
Marc Voigt, CEO, CFO, Chief Bus. Officer, Executive Director, Member of Audit and Risk Committee and Member of Remuneration Committee | ||
Matthew Gregorowski, IR Contact Officer |
Prima Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Prima Biomed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -30.29 | |||
Return On Asset | -15.25 | |||
Profit Margin | (227.54) % | |||
Operating Margin | (229.73) % | |||
Current Valuation | 38.96 M | |||
Shares Owned By Institutions | 4.39 % | |||
Number Of Shares Shorted | 137.1 K | |||
Price To Earning | (5.70) X | |||
Price To Book | 1.71 X | |||
Price To Sales | 14.25 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Prima Biomed using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Prima Stock
If you are still planning to invest in Prima Biomed check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prima Biomed's history and understand the potential risks before investing.
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Global Correlations Find global opportunities by holding instruments from different markets |